Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases

Fineline Cube Jul 11, 2022

China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...

R&D

Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment

Fineline Cube Jul 11, 2022

Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...

Company

CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development

Fineline Cube Jul 11, 2022

US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...

Company

Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal

Fineline Cube Jul 11, 2022

China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...

Company Legal / IP

Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001

Fineline Cube Jul 11, 2022

US-based Acer Therapeutics Inc. (Nasdaq: ACER) and Swiss partner Relief Therapeutics Holding SA (SWX: RLF)...

Company Deals

Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech

Fineline Cube Jul 11, 2022

Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...

Company Drug

OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC

Fineline Cube Jul 11, 2022

Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...

Company Drug

Hengrui Medicine’s SHR8554 Accepted for NMPA Review in Postoperative Pain

Fineline Cube Jul 11, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its market filing for SHR8554,...

R&D

Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics

Fineline Cube Jul 11, 2022

China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...

Company Drug

CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review

Fineline Cube Jul 11, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Ultra-Long-Acting Insulin Receives Clinical Trial Approval

Fineline Cube Jul 11, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product...

Company Deals

Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions

Fineline Cube Jul 11, 2022

Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB...

Policy / Regulatory

NMPA Issues New Vaccine Manufacturing and Distribution Rules

Fineline Cube Jul 11, 2022

China’s National Medical Products Administration (NMPA) has released the “Vaccine Manufacturing and Distribution Management Measures,”...

Company Drug

VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US

Fineline Cube Jul 11, 2022

China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study...

Company Deals

Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact

Fineline Cube Jul 11, 2022

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...

Company Deals

Hangzhou DAC Bio Partners with Janssen on ADC Development Deal

Fineline Cube Jul 11, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...

Policy / Regulatory

NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms

Fineline Cube Jul 8, 2022

The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...

Company Drug

Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy

Fineline Cube Jul 8, 2022

China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...

Company Drug

Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors

Fineline Cube Jul 8, 2022

China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...

Company Deals

Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M

Fineline Cube Jul 8, 2022

Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...

Posts pagination

1 … 703 704 705 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.